Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia – Commentary

Jonathan Weiss, Martin Peifer, Carmen D. Herling, Lukas P. Frenzel, and Michael Hallek

Disclosures: Competing interests: C.D.H, L.P.F and M.H. received research funding from Hofmann-La Roche. M.H. received consulting and/or speaker’s honoraria from Hofmann-La Roche. Research support was provided by AbbVie to M.H. AbbVie provided travel support to L.P.F. Consulting and/or speaker’s honoraria from AbbVie was obtained by L.P.F and M.H. The remaining authors declare no competing financial interests.

Contributions: JW performed the Experiments, analyzed the data and wrote the manuscript. MP contributed to the Analysis of the data. CDH and LPF provided samples. MH conceived the study and wrote the manuscript.